Mostrar el registro sencillo del ítem

dc.contributor.authorNaranjo Muñoz, Javier 
dc.contributor.authorBorrego, Francisco
dc.contributor.authorRocha, José Luis
dc.contributor.authorSalgueira Lazo, Mercedes
dc.contributor.authorMartín-Gomez, Maria Adoración
dc.contributor.authorOrellana, Cristhian
dc.contributor.authorMorales, Ana 
dc.contributor.authorVallejo, Fernando
dc.contributor.authorHidalgo, Pilar
dc.contributor.authorRodríguez, Francisca 
dc.contributor.authorGarófano, Remedios
dc.contributor.authorGonzález, Isabel
dc.contributor.authorEsteban, Rafael
dc.contributor.authorEspinosa, Mario
dc.contributor.authorAndalusian Group of ADPKD and Hereditary Kidney Diseases
dc.contributor.otherMedicinaes_ES
dc.date.accessioned2023-11-03T08:08:59Z
dc.date.available2023-11-03T08:08:59Z
dc.date.issued2022-09-29
dc.identifier.issn2296-858X
dc.identifier.urihttp://hdl.handle.net/10498/29558
dc.description.abstractBackground: Tolvaptan (TV) is the first vasopressin-receptor antagonist approved for the treatment of autosomal dominant polycystic kidney disease (ADPKD). No publications report TV experience in real clinical practice during the first year of treatment. Methods: A prospective study of an initial cohort of 220 rapidly progressing patients treated with TV for 12 months. The tolerability of TV, the evolution of the estimated glomerular filtration rate (eGFR), analytical parameters, and blood pressure were analyzed. Results: A total of 163 patients (78.2%) received TV for 1 year. The main causes of treatment withdrawal were the aquaretic effects (11%), eGFR deterioration (5%), and hepatic toxicity (2.3%). eGFR decreased significantly after 1 month of treatment without further changes. The decrease in eGFR in the first month was higher in patients with an initially higher eGFR. The eGFR drop during the first year of treatment with TV was lower than that reported by patients in the 2 years prior to TV treatment (-1.7 +/- 7.6 vs. - 4.4 +/- 4.8 mL/min, p = 0.003). Serum sodium and uric acid concentrations increased, and morning urinary osmotatity decreased in the first month, with no further changes. Blood pressure decreased significantly without changes in antihypertensive medication. Conclusion: TV treatment is well tolerated by most patients. Liver toxicity is very rare and self-limited. TV reduces eGFR in the first month without showing further changes during the first year of treatment. Patients with a higher starting eGFR will suffer a greater initial drop, with a longer recovery. We suggest using the eGFR observed after a month of treatment as the reference for future comparisons and calculating the rate of eGFR decline in patients undergoing TV treatment.es_ES
dc.formatapplication/pdfes_ES
dc.language.isoenges_ES
dc.publisherFRONTIERS MEDIA SAes_ES
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.sourceFrontiers in Medicine, Vol. 9, 2022es_ES
dc.subjectglomerular filtration rate (eGFR)es_ES
dc.subjecthepatic toxicityes_ES
dc.subjectpolycystic kidney disease (PKD)es_ES
dc.subjecttolvaptanes_ES
dc.subjecturinary osmolalityes_ES
dc.titleReal clinical experience after one year of treatment with tolvaptan in patients with autosomal dominant polycystic kidney diseasees_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.3389/fmed.2022.987092
dc.type.hasVersionVoRes_ES


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Esta obra está bajo una Licencia Creative Commons Atribución 4.0 Internacional